Literature DB >> 36197689

Distribution of High-Sensitivity Cardiac Troponin and N-Terminal Pro-Brain Natriuretic Peptide in Healthy Transgender People.

Dina N Greene1, Robert L Schmidt2, Robert H Christenson3, Jessica Rongitsch4, Katherine L Imborek5,6, Heather Rebuck3, Thomas S Lorey7, Amy K Saenger8, Matthew D Krasowski9.   

Abstract

Importance: Sex-specific differences in the commonly used cardiac biomarkers high-sensitivity cardiac troponin (hs-cTn) and N-terminal pro-brain natriuretic peptide (NT-proBNP) are apparent. There is an absence of medical literature delineating the concentration differences for these biomarkers in transgender individuals without cardiac disease. Objective: To determine the distribution of hs-cTn and NT-proBNP in healthy transgender people. Design, Setting, and Participants: In this cross-sectional prospective study, healthy transgender individuals prescribed testosterone or estradiol for 12 months or more were recruited from internal medicine and primary care clinics that specialize in transgender medical care between November 1, 2017, and July 1, 2018. Exposures: Testosterone or estradiol for 12 months. Main Outcomes and Measures: Concentrations for hs-cTnI (troponin I), hs-cTnT (troponin T), and NT-proBNP were measured.
Results: Transgender people prescribed testosterone (n = 79; mean [SD] age, 28.8 [7.8] years) or estrogen (n = 93; mean [SD] age, 35.1 [11.7] years) were recruited. The concentration of hs-cTn was significantly higher in transgender men relative to transgender women. For Abbott hs-cTnI levels, the median (IQR) concentration observed in transgender men and women was 0.9 (0.6-1.7) ng/L and 0.6 (0.3-1.0) ng/L, respectively. Results were similar across 2 additional hs-cTn assays. In contrast, NT-proBNP level was higher in transgender women. The median (IQR) NT-proBNP concentration was significantly higher in transgender women ( 49 [32-86] ng/L) than in transgender men (17 [13-27] ng/L). Conclusions and Relevance: Findings of this cross-sectional study suggest that the differences in concentration for hs-cTn and NT-proBNP between transgender men and women were similar to what is observed between cisgender men and women. Sex hormones, rather than sex assigned at birth, may be a stronger driver of the observed concentration differences between healthy men and women for biomarkers of cardiac disease.

Entities:  

Year:  2022        PMID: 36197689      PMCID: PMC9535541          DOI: 10.1001/jamacardio.2022.3299

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   30.154


  10 in total

1.  Cross-Sex Hormones and Acute Cardiovascular Events in Transgender Persons.

Authors:  Zil Goldstein; Carl Streed; Tamar Resiman; Monica Mukherjee; Asa Radix
Journal:  Ann Intern Med       Date:  2019-01-15       Impact factor: 25.391

Review 2.  Sex-Specific Versus Overall Clinical Decision Limits for Cardiac Troponin I and T for the Diagnosis of Acute Myocardial Infarction: A Systematic Review.

Authors:  Dorien M Kimenai; Emma B N J Janssen; Kai M Eggers; Bertil Lindahl; Hester M den Ruijter; Otto Bekers; Yolande Appelman; Steven J R Meex
Journal:  Clin Chem       Date:  2018-05-29       Impact factor: 8.327

3.  Clinical Laboratory Practice Recommendations for the Use of Cardiac Troponin in Acute Coronary Syndrome: Expert Opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine.

Authors:  Alan H B Wu; Robert H Christenson; Dina N Greene; Allan S Jaffe; Peter A Kavsak; Jordi Ordonez-Llanos; Fred S Apple
Journal:  Clin Chem       Date:  2018-01-17       Impact factor: 8.327

4.  Reference limits for N-terminal-pro-B-type natriuretic peptide in healthy individuals (from the Framingham Heart Study).

Authors:  Michael G Fradley; Martin G Larson; Susan Cheng; Elizabeth McCabe; Erin Coglianese; Ravi V Shah; Daniel Levy; Ramachandran S Vasan; Thomas J Wang
Journal:  Am J Cardiol       Date:  2011-08-23       Impact factor: 2.778

5.  Hematology reference intervals for transgender adults on stable hormone therapy.

Authors:  Dina N Greene; Gabrielle Winston McPherson; Jessica Rongitsch; Katherine L Imborek; Robert L Schmidt; Robert M Humble; Nicole Nisly; Nancy J Dole; Susan K Dane; Janice Frerichs; Matthew D Krasowski
Journal:  Clin Chim Acta       Date:  2019-02-13       Impact factor: 3.786

6.  Reference Intervals for Clinical Chemistry Analytes for Transgender Men and Women on Stable Hormone Therapy.

Authors:  Robert M Humble; Dina N Greene; Robert L Schmidt; Gabrielle Winston McPherson; Jessica Rongitsch; Katherine L Imborek; Nicole Nisly; Nancy J Dole; Susan K Dane; Janice Frerichs; Matthew D Krasowski
Journal:  J Appl Lab Med       Date:  2022-09-01

7.  Pediatric brain natriuretic peptide concentrations vary with age and sex and appear to be modulated by testosterone.

Authors:  Amy K Saenger; Daniel A Dalenberg; Sandra C Bryant; Stefan K Grebe; Allan S Jaffe
Journal:  Clin Chem       Date:  2009-08-13       Impact factor: 8.327

Review 8.  Assessing and Addressing Cardiovascular Health in People Who Are Transgender and Gender Diverse: A Scientific Statement From the American Heart Association.

Authors:  Carl G Streed; Lauren B Beach; Billy A Caceres; Nadia L Dowshen; Kerrie L Moreau; Monica Mukherjee; Tonia Poteat; Asa Radix; Sari L Reisner; Vineeta Singh
Journal:  Circulation       Date:  2021-07-08       Impact factor: 39.918

Review 9.  Sex-related differences in contemporary biomarkers for heart failure: a review.

Authors:  Navin Suthahar; Laura M G Meems; Jennifer E Ho; Rudolf A de Boer
Journal:  Eur J Heart Fail       Date:  2020-03-27       Impact factor: 15.534

10.  Sex Differences in Cardiac Troponin I and T and the Prediction of Cardiovascular Events in the General Population.

Authors:  Dorien M Kimenai; Anoop S V Shah; David A McAllister; Kuan Ken Lee; Athanasios Tsanas; Steven J R Meex; David J Porteous; Caroline Hayward; Archie Campbell; Naveed Sattar; Nicholas L Mills; Paul Welsh
Journal:  Clin Chem       Date:  2021-10-01       Impact factor: 12.167

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.